Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Mitoxantrone in advanced breast cancer: a phase II trial of the Southwest Oncology Group (1983)
    Springer
    Investigational new drugs 1 (1983), S. 181-184 
    Details
    ISSN: 1573-0646
    Keywords: mitoxantrone ; breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary 124 patients with metastatic breast cancer were entered into this phase II trial of mitoxantrone (DHAD). Patients were stratified prior to treatment as good or poor risk, and whether they had received previous therapy with an anthracycline derivative. Mitoxantrone was given every 21 days at a starting dose of 12 mg/m2 for good risk patients and 10 mg/m2 for poor risk patients. Among the group who had not received anthracyclines, 12 are fully or partially evaluable for response with five classified as good risk. One complete response, ongoing at 52 weeks was seen in this group. Of the seven poor risk patients, stable disease was seen in two. 103 patients with prior anthracycline exposure are fully or partially evaluable, 31 good risk and 72 poor risk. There were three partial responses in each group. Toxicity was primarily myelosuppression, and was more severe in the poor risk group. Mitoxantrone when used on this schedule has minimal activity among heavily pretreated patients with metastatic breast cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00172078
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Management of brain metastases from breast cancer by combination chemotherapy (1983)
    Springer
    Journal of neuro-oncology 1 (1983), S. 131-137 
    Details
    ISSN: 1573-7373
    Keywords: brain metastases ; breast cancer ; chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Since most patients with brain metastases from breast cancer have disseminated disease elsewhere and a dismal prognosis when treated by whole brain irradiation alone, we investigated the use of systemic chemotherapy in 66 such patients. Fifty-two percent (34 of 66 patients) demonstrated an objective response to this therapy which was similar to the results obtained in patients treated for extracranial metastases. Eighteen patients who subsequently had recurrence of brain metastases were successfully retreated with secondary chemotherapy. The median duration of remission in 34 responders was ten months. The median survival, from the time of chemotherapy for brain metastases, was 13.1 months in 34 responders (range 5–74+) vs. 3.0 months in 32 non-responders (P 〈 0.001). These findings suggest that systemic chemotherapy is effective in the treatment of patients with brain metastases from breast cancer by inducing remission and prolonging survival.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00182958
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 355-364 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant chemotherapy ; breast cancer ; estrogen receptor ; progesterone receptor
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In 1977 the National Surgical Adjuvant Breast and Bowel Project (NSABP) initiated a prospectively randomized clinical trial to evaluate the relative merits of 1-phenylalanine mustard and 5-fluorouracil (PF) with and without tamoxifen (T) as adjuvant therapy for patients with primary breast cancer and positive axillary nodes. A previous presentation of findings noted that there was a strong relationship between the outcome of those receiving PFT and the estrogen receptor (ER) and progesterone receptor (PR) content of their tumors. This report relates the outcome of the PF-treated patients in that trial with these tumor receptors. It indicates that the results observed following nonhormonal therapy (PF) are also related to tumor receptors. Both the disease-free survival (DFS) and survival (S) of women following PF therapy were influenced by the ER and PR content of their tumors. Subsequent to adjustment for other prognostic variables, the predictive influence of tumor ER persisted. Both the DFS (p = 0.0003) and the S (p = 0.00003) were significantly higher in those with ≥ 10 fmol tumor ER than in those with 〈 10 fmol ER. The PR significantly added to the predictive value of ER. Thus, this analysis is the first to demonstrate that having information on both ER and PR is important for predicting outcome of patients receiving adjuvant chemotherapy. The study does not provide information which correlates receptor status with the response of patients to adjuvant chemotherapy since there is no similar nonchemotherapy-treated group of patients in the trial. The findings continue to emphasize that there is a heterogeneity in outcome of breast cancer patients to adjuvant chemotherapy which is related to an increasing number of host and tumor variables. For proper assessment of overall results, it is essential that analyses employ tests for interaction to indicate homogeneity or heterogeneity of patient subsets and that adjustments be made for imbalances in tumor ER and PR as well as in other prognostic factors.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01807588
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Relationship between mammographic pattern and estrogen receptor content in breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 201-207 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; estrogen receptor ; mammographic pattern
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The mammographic pattern and its relationship to the estrogen receptor (ER) content was studied in 184 breast cancers. The tumors were divided into five radiographic subgroups: mass with spicules (A), diffuse (B), clusters of calcifications without a mass (C), circumscribed (D), and not visible at mammography (E). The ER content of tumors belonging to group A was higher than that of the other subgroups in both pre- and postmenopausal women. 121 tumors belonged to group A, of which 80% were ductal cancers. The tumors in groups B and C had very low ER values and those of groups D and E had intermediate values. The likelihood of finding a high estrogen receptor content of a tumor is thus greater when the tumor radiographically is seen as a mass with spicules than when seen as an increased attenuation or as only clusters of calcifications. It is suggested that patients with tumors belonging to group A should have a more favorable prognosis than patients with tumors belonging to groups B and C.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01803562
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Post-operative serum sialyltransferase levels and prognosis in breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 225-230 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; prognosis ; sialyltransferase ; tumor markers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Serum sialyltransferase (SST) activity was measured 10 days after mastectomy in 153 patients with operable breast cancer. Enzyme activity declined with time in storage (1–42 months). After correction for loss of activity in storage, patients with SST activity below the median value had a longer disease-free interval (DFI) than those with SST activity above the median, and this difference remained when patients were stratified by axillary nodal status, tumor size, and tumor grade. Survival was longer in patients with low SST activity. Postoperative elevation of SST indicates a poor prognosis in patients with operable breast cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01803565
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 6
    Electronic Resource
    Electronic Resource
    Quality control of estrogen receptor assays in the Netherlands (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 255-266 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; estrogen receptors ; lyophilization ; quality control ; routine receptor assays
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Lyophilized receptor-positive tissue powders and cytosols, prepared from calf uterus and human breast tumor tissue, are used to assess the validity of routine dextran-coated charcoal estrogen receptor assays. Since 1978 lyophilized reference preparations have been analyzed twice yearly by 18 laboratories in the Netherlands. During 8 consecutive trials 20 different lyophilized samples were studied. The inter-laboratory variability of estrogen receptor results decreased with time. Most laboratories found receptor values around the median value of all groups together, though some participants consistently reported estrogen receptor values that were higher or lower than the median. The variability of estrogen receptor results between labs seemed to be associated with cytosol dilution, determination of non-specific binding, concentration and volume of dextrancoated charcoal, and the use of single dose assays or Scatchard analysis. The agreement on the presence or absence of estrogen receptors was more than 98% for lyophilized reference samples with high receptor content. For samples with low receptor content 85% agreement was observed, while 12% of the assays performed on receptor-negative material were reported to be estrogen receptor-positive. The use of the same protein determination (Coomassie Brilliant Blue) and human serum albumin standard has decreased the interlaboratory variation coefficient of the protein results to 7.5%.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806699
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 7
    Electronic Resource
    Electronic Resource
    Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. S45 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant therapy ; breast cancer ; ovarian irradiation ; prednisone
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Following mastectomy, patients with operable breast cancer underwent postoperative irradiation of the chest wall and regional lymph nodes. They were then assigned at random to receive no further therapy, ovarian irradiation (2000 rad in five days) or ovarian irradiation in the same dosage plus prednisone, 7.5 mg daily. A total of 705 patients received the randomly assigned treatment and were followed for up to 15 years. In premenopausal patients who received ovarian irradiation, the recurrence of breast cancer was delayed and survival prolonged, but not significantly. In premenopausal women aged 45 years or more, ovarian irradiation plus prednisone therapy significantly delayed the recurrence of breast cancer (p = 0.04) and prolonged survival (p = 0.02). No value was demonstrated for ovarian irradiation with or without prednisone therapy in postmenopausal patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01855127
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 8
    Electronic Resource
    Electronic Resource
    Adjuvant endocrine therapy, cytotoxic chemotherapy, and immunotherapy in stage-II breast cancer: Five-year results (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. S61 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant treatment ; breast cancer ; estrogen receptors ; tamoxifen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Five-year results of a prospective, randomized clinical trial of three treatment regimes—(a) cytoxan, methotrexate, and 5-fluorouracil (CMF); (b) CMF plus the antiestrogen drug, tamoxifen (CMFT); and (c) CMFT plus bacillus Calmette-Guerin (BCG) vaccinations—in 312 women with stage-II breast cancer are reported. Estrogen receptors (ER) were measured in all of the primary tumors. Addition of tamoxifen to CMF therapy significantly decreased the number of recurrences at five years in ER positive patients with four or more positive axillary lymph nodes. Addition of tamoxifen to CMF had no effect on disease-free survival in ER-positive patients with 1–3 positive axillary lymph nodes or in patients with ER-negative tumors. Addition of BCG vaccinations had no discernible effect on disease-free survival. ER measurements in the primary tumor provide important prognostic information regardless of treatment, with ER-positive patients having lower recurrence rates and mortality after five years. ER measurements also have predictive value for response to endocrine therapy. Further follow-up is needed to determine whether tamoxifen is delaying recurrence or preventing it in a subset of these patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01855129
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 9
    Electronic Resource
    Electronic Resource
    Prognostic factors in primary breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. S69 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; estrogen receptor ; progesterone receptor ; prognostic factors
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Estrogen receptor (ER) has been well documented as an important predictor of long disease-free intervals and survival for patients with primary breast cancer (1). In advanced breast cancer it has been hypothesized that the presence of progesterone receptor (PR) might be a more sensitive marker for predicting response to endocrine therapy (2,3). We have recently found that PR was more important than ER in predicting diseasefree survival for a group of patients with stage-II breast disease that was treated according to a randomized protocol (Clark et al., submitted for publication). This report examines the generality of that result by extending our analysis to include patients from other institutions. The additional patients were not treated according to a rigid clinical protocol, but rather received treatments in much the same way as the majority of breast cancer patients in a community practice. Of interest was whether the relationship between steroid receptors and disease-free survival that we have previously reported would hold with this new group of patients with different demographic and treatment profiles. The relationships between steroid receptor levels and both disease-free and overall survival were examined in detail.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01855130
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 10
    Electronic Resource
    Electronic Resource
    Screening for breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 143-156 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; mammography ; physical examination ; radiation ; screening
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Screening for breast cancer using the combination of physical examination of the breasts and mammography was effective in women age 50 or more in the HIP study. However, major questions remain, especially the benefit of screening women age 40–49, and the independent effect of mammography. Such questions can only be answered by large-scale randomized controlled trials, and trials to answer these questions are now underway in Canada (the NBSS) and Sweden. Only the NBSS, however, is attempting to replicate the HIP study in women age 40–49, and to evaluate the additional contribution of mammography to annual physical examination in women age 50–59. The Swedish studies are evaluating the effectiveness of mammography alone, while studies in Britain will help to evaluate breast self-examination (BSE) and biannual mammography with annual physical examination. Because much of the benefit in HIP could have derived from the physical examination, it is necessary to complete the present trials before population-based screening for breast cancer using mammography can be advocated. Trials are justifiable because the risk of mammographic screening seems likely to be negligible, and the use of the combination of annual mammography and physical examination to be cost-effective. In the meantime, there seems no immediate substitute on a population basis for efficient physical examination of the breasts by primary care physicians coupled with breast self-examination by the woman. Techniques such as ultrasound and diaphanography seem unlikely to supplant mammography in screening, and in any case, have to be evaluated in comparison with mammography.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01803557
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 11
    Electronic Resource
    Electronic Resource
    Characterization of insulin regulation of lipid synthesis in MCF-7 human breast cancer cells (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 279-285 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; insulin ; lipids ; MCF-7 cells
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Stimulation of lipid synthesis by insulin in MCF-7 human breast cancer cells is characterized by an increase in acetate incorporation into long-chain fatty acids. The effects occurs in the absence of an increase in glucose uptake by the cells, and cannot be explained by a decrease in turnover of cellular fatty acids. Differential substrate experiments as well as direct measurement of enzyme activities indicate that insulin stimulates increases in activity of the first enzyme of the de novo pathway, acetyl CoA carboxylase. [3 2Pi] incorporation into phospholipids is also stimulated by insulin. Thin layer chromatography reveals five peaks of [3 2Pi]-labeled phospholipids corresponding in mobility to the following standards: lysophosphatidylcholine, sphingomyelin, phosphatidylcholine, phosphatidylinositol, and phosphatidylethanolamine. [3 2Pi] incorporation into each of these peaks is stimulated, although the degree of stimulation varies.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806701
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 12
    Electronic Resource
    Electronic Resource
    Interrupted pregnancy as an indicator of poor prognosis in T1, 2, N0, M0 primary breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 339-344 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; histology ; interrupted pregnancy ; prognosis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary We examined the records of women with primary breast cancer for a history of pregnancy and live births. The patients were all histopathologic T1, 2, N0, M0 white females, untreated post modified radical mastectomy. Patients with a history of interrupted pregnancies have a significantly shorter time to recurrence than those with normal pregnancy history. A trend toward a lower incidence of highly differentiated histological pattern is also observed in cancers from these patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01807586
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 13
    Electronic Resource
    Electronic Resource
    Psychosocial and physical outcomes of primary breast cancer therapy: Mastectomy vs excisional biopsy and irradiation (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 377-382 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; excisional biopsy ; mastectomy ; psychosocial outcome ; radiation
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Thirty-eight patients treated for primary breast cancer as part of a prospective randomized clinical trial were questioned retrospectively as to their psychosocial adaptation to treatment. Twenty patients had received mastectomy and eighteen had received excisional biopsy plus radiation of the intact breast. Aside from body image concerns, there were no marked psychosocial differences detected between these groups. Previous studies emphasizing serious psychological problems in mastectomy patients and fewer such problems in nonmastectomy patients may be influenced by biases that are not present in a randomized study design.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01807591
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 14
    Electronic Resource
    Electronic Resource
    Chemotherapy responsiveness of human breast tumors in the 6-day subrenal capsule assay: An update (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 33-38 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; drug resistance ; drug screening ; subrenal capsule assay
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Feasibility of utilizing the 6-day subrenal capsule (SRC) assay to screen drugs against fresh surgical explants of human tumors was confirmed by testing six clinically active chemotherapeutic agents against 141 human breast cancers. Response rates of the six drugs obtained in the assay compared favorably with clinical response rates for the same drugs as reported by Carter (5). The evaluable assay rate for breast tumors was 92% as compared to 89% for gynecologic tumors. Innate drug resistance was indicated with 16 of 57 tumors (28%) which did not respond to any of the six agents tested. Differences in responsiveness of tumors to each agent in a potential three-drug combination of either CMF or CAF suggest that the effectiveness of multiagent therapy might be enhanced if the individual agents of a potential drug combination were selected on the basis of tumor sensitivity to each of the agents in a predictive assay. Although cross-resistance between L-PAM and cytoxan was demonstrated and was statistically significant, 31% of these tumors responded individually to either one or the other agent, suggesting caution in extrapolating concomitance in activity between these two alkylators.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806232
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 15
    Electronic Resource
    Electronic Resource
    Relationship of cyclic AMP binding capacity and estrogen receptor to hormone sensitivity in human breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 67-72 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; cAMP binding capacity ; endocrine treatment ; estrogen receptor ; hormone sensitivity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Estrogen receptor (ER) and total binding capacity for cyclic AMP (cAR) were measured in cytosols from human mammary tumors. Patients with advanced, evaluable breast cancer were biopsied before the start of endocrine treatment, and ER and cAR measurements were performed. All patients included in this study were ER positive. Sixteen of 30 patients (53%) had an objective response to endocrine treatment. When ER and cAR were expressed as a ratio and this ratio was related to treatment response, it was found that all objective responders had ratio values above 2.5 × 10−3. Nine of 14 nonresponders had ER/cAR ratios below this value. In our limited series of patients a threshold limit of 2.5 × 10−3 would have correctly predicted the response to endocrine treatment in 25 of 30 patients (83%). In patients with ER values below 100 fmol/mg protein and PgR negative or unknown, cAR might strengthen the predictive value of steroid receptor measurements.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806235
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 16
    Electronic Resource
    Electronic Resource
    Effects of drugs associated with hyperprolactinemia on plasma steroids and on steroid receptors and metabolism in human breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 331-338 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; estrogen receptor ; hyperprolactinemic drugs ; prolactin ; steroid biosynthesis ; steroid hormones
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Certain commonly taken pharmaceutical preparations induce increased levels of plasma prolactin. The effects of these drugs on (a) tumor steroid receptors and metabolism, and (b) plasma hormones and hormone binding proteins have been studied in postmenopausal women with breast cancer. Two groups have been compared, 18 patients on drug treatment for at least 2 months and 15 subjects with no history of drug ingestion. Patients taking medication had significantly higher levels of plasma prolactin compared with control women. No significant difference was observed between the groups with regard to the plasma concentrations of dehydroepiandrosterone (DHA) and its sulphate (DHS), testosterone, estrone, estradiol-17β, sex hormone binding globulin (SHBG), and albumin. Similarly, no difference was observed between these two groups with regard to estrogen receptor (ER), progestogen receptor (PR), or androgen receptor (AR) levels in the tumors nor their ability to metabolize (7−3H) testosterone. It is considered that the ingestion of these drugs does not affect tumor mechanisms involving steroids.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01807585
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 17
    Electronic Resource
    Electronic Resource
    Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 91-95 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant therapy ; breast cancer ; CMF ; cyclophosphamide
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary After total mastectomy and partial axillary dissection, 805 premenopausal women with stage II breast cancer were randomized to receive postoperative radiotherapy (RT) alone, RT + cyclophosphamide (C) for 12 monthly cycles, or RT + cyclophosphamide/methotrexate/5-fluorouracil (CMF) for 12 monthly cycles. At 3 years actuarial relapse-free survival for RT + C and RT + CMF was significantly better than for RT alone (p = 0.0009 and 0.0001, respectively). There was no significant difference in relapse-free survival between RT + C and RT + CMF. C resulted in more pronounced haematologic toxicity and a higher frequency of amenorrhoea and of alopecia than CMF, while CMF resulted in more pronounced nausea and stomatitis than C. In the preliminary results, C alone may be as effective as CMF in prolonging relapse-free survival in premenopausal women with stage II breast cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806239
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 18
    Electronic Resource
    Electronic Resource
    Symposium introduction and overview adjuvant therapy of breast cancer: Perspectives for the '80s (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. S3 
    Details
    ISSN: 1573-7217
    Keywords: aduvant therapy ; breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In July of 1982, a symposium was held in Colorado Springs, Colorado, entitled “Adjuvant Therapy of Breast Cancer: Perspectives for the 80's”. Information in this area is evolving so quickly that it was extremely useful to gather leading researchers in the field for informal presentations and discussion to exchange ideas and analyze data. Hopefully, this exchange of information will lead to a more cooperative effort in protocol development and to protocols which ask not only treatment questions, but also biologic questions.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01855121
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 19
    Electronic Resource
    Electronic Resource
    Adjuvant therapy of breast cancer: The Southwest Oncology Group experience (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. S27 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant therapy ; breast cancer
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The Southwest Oncology Group in a prospective randomized study compared one year of adjuvant combination chemotherapy with continuous CVFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone) to two years of intermittent L-phenylalanine mustard (L-PAM) in women with operable breast cancer with histologically positive axillary lymph nodes. In fully and partially evaluable patients with a 68-month median follow-up, treatment failures have occurred in 27% of 172 receiving CMFVP and 47% of 186 women given L-PAM (p = 0.002). The advantage for women receiving CMFVP was seen for all subsets regardless of menopausal status except among women who were premenopausal and had 1–3 positive nodes. Based on this study, a second study was implemented using both the estrogenreceptor (ER) content of the primary tumor and axillary nodal status to select therapy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01855124
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 20
    Electronic Resource
    Electronic Resource
    Antiestrogen treatment of postmenopausal women with primary high risk breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 77-84 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; estrogen receptor ; progesterone receptor ; risk factors ; tamoxifen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The role of antiestrogen treatment in high risk postmenopausal patients with primary breast cancer is currently evaluated in a nationwide, prospective randomized trial conducted by the Danish Breast Cancer Cooperative Group. The primary treatment is total mastectomy and radiotherapy. As of February 1, 1982, 720 women were randomized to treatment with tamoxifen (30 mg daily for 1 year) and 691 women were randomized to no further therapy. Life-table analysis after 36 months shows a difference in recurrence rates of 9% (p = 0.19) in favor of the tamoxifen-treated patients. The material has been analyzed with respect to established prognostic factors such as age, degree of anaplasia, tumor size, and number of positive nodes. The rates of recurrent disease are lower in all subsets of patients treated with tamoxifen, but are only statistically significant in patients 50–59 years of age or with 4 or more positive lymph nodes. Regardless of treatment, ER negative patients have a 23% higher recurrence rate than ER positive patients after 18 months of analysis (p = 0.0033); this represents an approximate doubling of risk, and is independent of age, degree of anaplasia, tumor size, or lymph node status. With regard to PgR status, there is 11% higher recurrence rate in the PgR negative than in the PgR positive patients (p = 0.097).
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806237
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 21
    Electronic Resource
    Electronic Resource
    Pathology of primary tumors and axillary lymph nodes in British and Japanese women with breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 165-169 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; Britain ; histology ; Japan
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Histopathologic features of the primary tumor and axillary lymph nodes from 97 consecutive patients with breast cancer from Japan were compared with those from 164 patients from England. Between the two groups, there were statistically significant differences in the morphology of the primary tumors regarding nuclear grade and patterns of tumor infiltration. In axillary lymph nodes, sinus histiocytosis was much more common in Japanese cases than in British cases, and was related to a diminished frequency of axillary node metastases. Germinal centers were also more common in the nodes of Japanese patients and were similarly associated with diminished frequency of metastases.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01803559
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 22
    Electronic Resource
    Electronic Resource
    Prednimustine in combination with methotrexate and 5-fluorouracil in advanced breast cancer: A phase I–II study (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 85-89 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; clinical trials ; prednimustine
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Forty-seven patients with advanced breast cancer were treated with a combination of prednimustine (P), methotrexate (M), 5-fluorouracil (F), and tamoxifen (TAM). Twenty-six patients received P, 80 mg/m2 day 1–5 (series I) and 21 patients received P, 100 mg/m2 day 1–5 (series II). Both series of patients received M, 40 mg/m2 day 1 and 8 and F, 600 mg/m2 day 1 and 8 with a cycle duration of 4 weeks. All patients received TAM 20 mg twice daily. As concerns the haematologic toxicity, WBC were depressed significantly more often than platelet counts, and during the first 3 cycles 70% of the patients had a WBC nadir corresponding to toxicity grade II or more. No signs of cumulative haematologic toxicity were observed. Nausea and vomiting were registered in 40 out of 47 patients but in 35 of these only of grade I–II. Only one patient developed alopecia requiring a wig. The response to treatment could be evaluated in 28 patients, 21 of whom experienced response (CR or PR) of a median duration of 13 months. In conclusion, it seems that prednimustine can be safely used in combination with methotrexate and 5-fluorouracil. The frequency of alopecia is definitely lower than with CMF. Whether this relates also to subjective side effects will require a randomized study, as will a final conclusion concerning the efficacy compared to that of CMF.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01806238
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 23
    Electronic Resource
    Electronic Resource
    Use of ceruloplasmin levels to monitor response to therapy and predict recurrence of breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 221-224 
    Details
    ISSN: 1573-7217
    Keywords: Adjuvant therapy ; breast cancer ; ceruloplasmin ; recurrence prediction ; response to therapy ; tumor markers
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Ceruloplasmin (CP), an acute phase reactant, has been found to be elevated in patients with various tumors including breast cancer. We found that the CP level was elevated in 89% of 103 patients with metastatic breast cancer. In 27 patients with measurable metastatic disease that responded to treatment the mean CP level fell by 35% (p〈0.001) and in 22 patients whose disease progressed on treatment, the mean CP level rose by 44% (p〈0.001). Of those patients with Stage II breast cancer that were treated with adjuvant chemotherapy, only 6% of patients with a normal post mastectomy CP level have recurred, whereas 44% of patients with an elevated post mastectomy CP level have recurred (p〈0.01). In following patients with breast cancer, we noted that in those patients that recurred, the CP level became elevated 16–34 weeks prior to any clinical evidence of metastases. We also noted that the CP level became elevated after initially falling in patients receiving adjuvant chemotherapy and on occasion, the initially elevated CP level did not even fall. These circumstances may represent resistant microscopic disease, so that changing to a noncross-resistant chemotherapeutic regimen might be appropriate.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01803564
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 24
    Electronic Resource
    Electronic Resource
    Lack of efficacy of xeroradiography to preoperatively detect axillary lymph node metastases in breast cancer (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. 373-376 
    Details
    ISSN: 1573-7217
    Keywords: axillary metastases ; breast cancer ; xeroradiography
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Xeroradiography of the axilla was performed in 132 patients with operable breast cancer to investigate the status of the axillary lymph nodes. Pathologic findings were correlated with the results of clinical examination and xeroradiographic findings. Xeroradiography does not appear to have improved our ability to identify axillary lymph node metastases in patients with breast cancer.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01807590
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 25
    Electronic Resource
    Electronic Resource
    Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: An interim report (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. S7 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant therapy ; breast cancer ; tamoxifen
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary This trial studied the possibility that tamoxifen, added to L-phenylalanine mustard and 5-fluorouracil, enhances the established benefit of the latter two drugs in treatment of women with breast cancer and positive axillary nodes. The addition of tamoxifen resulted in a 25% decrease in treatment failure at 24 months and a 23% decrease at 36 months. In patients ≥50 years old, there was a 48% reduction at 24 months and a 39% reduction at 36 months. This advantage was statistically significant at both two and three years' follow-up (p 〈 0.001). Higher receptor levels were associated with a greater probability of disease-free survival. Patients ≤49 years old were less responsive. There was some evidence at 24 months that patients in this age group with four or more positive nodes who also had high ER levels might benefit from tamoxifen. At 36 months, however, this benefit was no longer evident. This form of adjuvant therapy is not recommended in patients ≤49 years of age whose tumor estrogen and progesterone levels are below 10 fmol; there is an appearance of benefit in patients ≥50 with low estrogen and progesterone levels, and stronger evidence of benefit when these levels are high among the older group of patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01855122
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 26
    Electronic Resource
    Electronic Resource
    Adjuvant chemotherapy in stage-II breast cancer: An overview of the NSABP clinical trials (1983)
    Springer
    Breast cancer research and treatment 3 (1983), S. S19 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant therapy ; breast cancer ; drug combinations
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Data derived from 1848 patients entered into three adjuvant chemotherapy protocols are presented. The three studies were performed sequentially and were designed to identify patient subsets responding to one, two, or three chemotherapeutic agents. Comparison of disease-free survival in patients receiving L-PAM or placebo disclosed that L-PAM was beneficial in patients ⩽49 years of age, but not in women ⩾50 years. Further analysis indicated that the subset of patients ⩽49 years with 1–3 positive nodes sustained the greatest increment in disease-free survival with single-agent L-PAM. The addition of 5-FU to L-PAM was superior to L-PAM alone in patients ⩾50 years of age, particularly those with ⩾4 positive nodes. The three-drug combination of L-PAM, 5-FU, and methotrexate failed to provide a benefit over and above that achieved by the L-PAM-5-FU combination in all subsets examined. The results underscore the heterogeneous response to chemotherapy demonstrated by patient subsets characterized on the basis of age and nodal status. The implications of the findings relative to the current status of adjuvant therapy are discussed.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01855123
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 27
    Electronic Resource
    Electronic Resource
    Phase II evaluation of rubidazone (NSC-164011) in advanced carcinoma of the breast (1983)
    Springer
    Investigational new drugs 1 (1983), S. 315-319 
    Details
    ISSN: 1573-0646
    Keywords: rubidazone ; breast cancer ; Phase II study
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary The SWOG carried out a Phase II evaluation of rubidazone in patients with advanced breast cancer. Good risk patients were given rubidazone 150 mg/m2 IV every three weeks. Poor risk patients were given a 25% dose reduction at the start of treatment. Rubidazone dose was increased or decreased depending on toxicity. One patient went into complete remission, four had partial remission and nine had stable disease. Forty-two patients showed increased disease on treatment. No cardiotoxicity was seen, but other common toxicities noted included mostly mild to moderate myelosuppression, nausea, vomiting and alopecia. This study failed to indicate significant antitumor activity of rubidazone in patients with advanced breast carcinoma.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00177415
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...